Advertisement
Advertisement
ALZN
Alzamend Neuro, Inc. Common Stock
1.46
USDSponsored
+0.09
+6.57%
Aug 10, 16:00 UTC -4
Closed
After-Market
1.47
+0.01
+0.34%
ALZN Earnings Reports
Positive Surprise Ratio
ALZN beat 10 of 18 last estimates.
56%
Next Report
Date of Next Report
Sep 08, 2026
Estimate for Q1 27 (Revenue/ EPS)
--
/-$0.68
Implied change from Q4 26 (Revenue/ EPS)
--
/+44.68%
Implied change from Q1 26 (Revenue/ EPS)
--
/-46.88%
Alzamend Neuro, Inc. Common Stock earnings per share and revenue
On Jul 22, 2026, ALZN reported earnings of -0.47 USD per share (EPS) for Q4 26, beating the estimate of -0.68 USD, resulting in a 31.23% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +4.13% price change (close before vs. close after earnings).
Looking ahead to Q1 27, 4 analysts forecast an EPS of -0.68 USD, with revenue projected to reach -- USD, implying an increase of 44.68% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bionano Genomics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.69
Actual
-$0.64
Surprise
+8.40%
Biohaven Ltd.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.74
Actual
-$0.91
Surprise
-21.67%
Alamar Biosciences, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.22
Surprise
+33.83%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.55
Actual
-$0.61
Surprise
-9.83%
Enanta Pharmaceuticals, Inc
Report Date
Aug 10, 2026 For Q3 26
Estimate
-$0.52
Actual
-$0.67
Surprise
-28.80%
Rocket Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
$0.24
Actual
-$0.15
Surprise
-160.80%
Palisade Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.05
Surprise
+6.19%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.19
Surprise
+6.86%
Orchestra BioMed Holdings, Inc. Ordinary Shares
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.38
Surprise
+4.95%
Nkarta, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.54
Surprise
-40.81%
FAQ
What were Alzamend Neuro, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2026?
For Q4 2026, Alzamend Neuro, Inc. Common Stock reported EPS of -$0.47, beating estimates by 31.23%, and revenue of $0.00, 0% as expectations.
How did the market react to Alzamend Neuro, Inc. Common Stock's Q4 2026 earnings?
The stock price moved up 4.13%, changed from $1.21 before the earnings release to $1.26 the day after.
When is Alzamend Neuro, Inc. Common Stock expected to report next?
The next earning report is scheduled for Sep 08, 2026.
What are the forecasts for Alzamend Neuro, Inc. Common Stock's next earnings report?
Based on 4
analysts, Alzamend Neuro, Inc. Common Stock is expected to report EPS of -$0.68 and revenue of -- for Q1 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement